Company Overview
- Website
- replimune.com
- Phone
- (781) 222-9600(202) 930-4762
- Employees
- 353
- Founded in
- 2015
- Industry
- BioTech/Drugs
- NAICS Codes
-
54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services5417 - Scientific Research and Development Services54171 - Research and Development in the Physical, Engineering, and Life Sciences541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- SIC Codes
-
87 - Engineering, Accounting, Research, Management, and Related Services873 - Research, Development, and Testing Services
Financials & Stats
Revenue
$70B
Total Funding Amount
$376M
Recent News & Media
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE) | Journal of Clinical Oncology
- Jul 8, 2025
- ascopubs.org
A multicenter, open-label study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab plus bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC).
- Jan 27, 2025
- ascopubs.org
Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat
- Nov 22, 2024
- stocktwits.com
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.
- May 29, 2024
- ascopubs.org
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.
- May 29, 2024
- ascopubs.org
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab plus bevacizumab for the treatment of patients with advanced colorectal carcinoma.
- Jan 22, 2024
- ascopubs.org
Who is Replimune Inc
Replimune Inc. is a biotechnology company based in Woburn, Massachusetts. The company employs 353 people and generated $69.5 million in revenue. Replimune focuses on developing oncolytic immunotherapies, a type of cancer treatment designed to activate the body's immune system to fight tumors. Their therapies aim to create a long-lasting, comprehensive anti-tumor response. Replimune distinguishes itself through its pioneering work in oncolytic immunotherapies, seeking to make cancer a curable disease. For more information, visit Replimune's website at replimune.com.